Authors:
PASSALI D
CALEARO C
CONTICELLO S
ANTONELLI A
ARSALAN E
BARBIERI A
BERNARDESCHI P
BOCCUZZI V
CASONI M
COCCO M
COLLETTI V
CROCE G
DANNA M
DEBENEDETTO M
DEGREGORIO S
DIGREGORIO E
DINASSO F
FABBRI F
FELISATI D
STORCHI OF
GALLI S
GIACCAI F
GRANDE F
LAUDADIO P
LUVARA A
MARCATO D
MARCHIORI G
MARCUCCI L
MESSINA D
MIANI P
NAPOLITANO S
PANTALENA V
PASTORE A
PELLEGRINO S
PERAZZITTI L
PINTUCCI JP
PRECERUTTI G
PUXEDDU P
SAVOCA A
SENSINI I
SEVERINI S
SPERATI G
SPINAZZOLA G
TASSINI G
ZERILLO G
Citation: D. Passali et al., PIDOTIMOD IN THE MANAGEMENT OF RECURRENT PHARYNGOTONSILLAR INFECTIONSIN CHILDHOOD, Arzneimittel-Forschung, 44-2(12A), 1994, pp. 1511-1516
Authors:
GEBBIA V
AGOSTARA B
CALLARI A
ZERILLO G
RESTIVO G
SPECIALE R
CUPIDO G
INGRIA F
SPATAFORA G
FAZIO L
GALLINA S
ZERILLO F
LOBUE P
TERMINI G
LOMBARDO F
VALENZA R
TESTA A
CANNATA G
CIMINO A
GEBBIA N
Citation: V. Gebbia et al., HEAD AND NECK-CARCINOMA WITH DISTANT METASTASES - A RETROSPECTIVE ANALYSIS OF 44 CASES TREATED WITH CISPLATIN-BASED CHEMOTHERAPEUTIC REGIMENS, Anticancer research, 13(4), 1993, pp. 1129-1131
Authors:
GEBBIA V
TESTA A
VALENZA R
ZERILLO G
RESTIVO S
CUPIDO G
INGRIA F
BARBACCIA C
SPADAFORA G
CANNATA G
GEBBIA N
Citation: V. Gebbia et al., A PHASE-II STUDY OF LEVOFOLINIC ACID AND 5-FLUOROURACIL PLUS CISPLATIN IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS-CELL CARCINOMA, Oncology, 50(6), 1993, pp. 490-494
Authors:
GEBBIA V
ZERILLO G
RESTIVO G
SPECIALE R
CUPIDO G
LOBUE P
INGRIA F
GALLINA S
SPATAFORA G
TESTA A
CANNATA G
CIMINO A
GEBBIA N
Citation: V. Gebbia et al., CHEMOTHERAPEUTIC TREATMENT OF RECURRENT AND OR METASTATIC NASOPHARYNGEAL CARCINOMA - A RETROSPECTIVE ANALYSIS OF 40 CASES, British Journal of Cancer, 68(1), 1993, pp. 191-194
Authors:
GEBBIA V
VALENZA R
TESTA A
ZERILLO G
RESTIVO S
CUPIDO G
INGRIA F
SPADAFORA G
BARBACCIA C
CANNATA G
CIPOLLA C
GEBBIA N
Citation: V. Gebbia et al., WEEKLY 5-FLUOROURACIL AND FOLINIC ACID PLUS ESCALATING DOSES OF CISPLATIN WITH GLUTATHIONE PROTECTION IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER, Medical oncology and tumor pharmacotherapy, 9(4), 1992, pp. 165-168